Detalhe da pesquisa
1.
A phase 2 study of pembrolizumab after autologous stem cell transplantation in patients with T-cell non-Hodgkin lymphoma.
Blood
; 142(7): 621-628, 2023 08 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-37319432
2.
Autologous transplant vs chimeric antigen receptor T-cell therapy for relapsed DLBCL in partial remission.
Blood
; 139(9): 1330-1339, 2022 03 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34570879
3.
A multi-cohort phase 1b trial of rituximab in combination with immunotherapy doublets in relapsed/refractory follicular lymphoma.
Ann Hematol
; 103(1): 185-198, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-37851072
4.
Clinical efficacy and safety of chimeric antigen receptor T-cell therapy for mantle cell lymphoma with secondary central nervous system involvement.
Br J Haematol
; 203(5): 774-780, 2023 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37584155
5.
PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation.
Blood
; 134(1): 22-29, 2019 07 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30952672
6.
Checkpoint blockade treatment sensitises relapsed/refractory non-Hodgkin lymphoma to subsequent therapy.
Br J Haematol
; 191(1): 44-51, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32430944
7.
Impact of Treatment Beyond Progression with Immune Checkpoint Blockade in Hodgkin Lymphoma.
Oncologist
; 25(6): e993-e997, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32275786
8.
Improved survival in cHL with novel agents.
Blood
; 141(22): 2666-2668, 2023 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37261856
9.
Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma.
Blood
; 129(10): 1380-1388, 2017 03 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-28073785
10.
Interim FDG-PET/CT for Response Assessment of Lymphoma.
Semin Nucl Med
; 53(3): 371-388, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36376131
11.
Minimal residual disease in patients with diffuse large B-cell lymphoma undergoing autologous stem cell transplantation.
Blood Adv
; 7(17): 4748-4759, 2023 09 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36399518
12.
Interim Positron Emission Tomography During Frontline Chemoimmunotherapy for Follicular Lymphoma.
Hemasphere
; 7(2): e826, 2023 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-36713355
13.
A multicenter retrospective study of polatuzumab vedotin in patients with large B-cell lymphoma after CAR T-cell therapy.
Blood Adv
; 6(9): 2757-2762, 2022 05 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35240681
14.
Prognostic value of minimal residual disease among patients with classical Hodgkin lymphoma undergoing autologous stem cell transplantation.
Leuk Lymphoma
; 63(12): 2912-2917, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-35938581
15.
Immune Reconstitution following High-Dose Chemotherapy and Autologous Stem Cell Transplantation with or without Pembrolizumab Maintenance Therapy in Patients with Lymphoma.
Transplant Cell Ther
; 28(1): 32.e1-32.e10, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34670169
16.
Outcomes and Utilization Trends of Front-Line Autologous Hematopoietic Cell Transplantation for Mantle Cell Lymphoma.
Transplant Cell Ther
; 27(11): 911.e1-911.e7, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34450333
17.
Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma.
Leukemia
; 35(9): 2672-2683, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-33658659
18.
Autologous stem cell transplantation after anti-PD-1 therapy for multiply relapsed or refractory Hodgkin lymphoma.
Blood Adv
; 5(6): 1648-1659, 2021 03 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-33710337
19.
Immune and Cell Therapy in Non-Hodgkin Lymphoma.
Cancer J
; 26(3): 269-277, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32496460
20.
Rituximab/bendamustine and rituximab/cytarabine induction therapy for transplant-eligible mantle cell lymphoma.
Blood Adv
; 4(5): 858-867, 2020 03 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32126141